Literature DB >> 2714931

Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival.

R J Brescia1, N Dubin, R I Demopoulos.   

Abstract

Eighty-five patients, 52 with endometrioid carcinoma (EC), nine with mixed endometrioid and clear cell carcinoma (MC), and 24 with clear cell carcinoma (CC), were studied to determine if prognosis was affected by (a) mixed tumor histology, (b) grade of the endometrioid component in ECs, and MCs, (c) presence of benign or malignant squamous differentiation in ECs, (d) solid versus tubular histology in CCs, (e) endometriosis in the same ovary as the tumor or elsewhere in the pelvis, (f) tumor stage, (g) patient age, or (h) presence of a coexisting carcinoma of the endometrium. The 5 year survivals for the ECs, MCs, and CCs were 52%, 22%, and 69%, respectively, for all stages. The 5 year survivals for Stage I ECs and CCs were 82% and 93%, respectively. None of these differences were statistically significant. Higher stages of disease for all three tumor types and higher grades of the endometrioid component of the ECs and the MCs were associated with significantly decreased survival. Patients with CCs had a significantly increased incidence of pelvic endometriosis (67%) versus patients with ECs (17%) or MCs (22%) (p less than 0.001). Survival was not significantly affected by benign or malignant squamous differentiation in ECs, tubular differentiation in CCs, patient age, the presence of endometriosis, or a coexisting carcinoma of the endometrium.

Entities:  

Mesh:

Year:  1989        PMID: 2714931     DOI: 10.1097/00004347-198906000-00006

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  Racial differences in stage at diagnosis and survival from epithelial ovarian cancer: a fundamental cause of disease approach.

Authors:  Seijeoung Kim; Therese A Dolecek; Faith G Davis
Journal:  Soc Sci Med       Date:  2010-04-22       Impact factor: 4.634

2.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

3.  Clear cell carcinoma of ovary with squamous metaplasia: A unique histopathological observation.

Authors:  Prasenjit Das; Geetika Singh; Narender Kumar; Roopa Hariprasad; Amit K Dinda; Lalit Kumar; Sandeep R Mathur
Journal:  Indian J Med Paediatr Oncol       Date:  2011-07

4.  HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.

Authors:  Masaki Fujimura; Noriyuki Katsumata; Hiroshi Tsuda; Naoko Uchi; Satomi Miyazaki; Takao Hidaka; Masatoshi Sakai; Shigeru Saito
Journal:  Jpn J Cancer Res       Date:  2002-11

Review 5.  Intraoperative consultation for ovarian tumors.

Authors:  Insun Kim
Journal:  Yeungnam Univ J Med       Date:  2019-06-11

6.  A rare case of synchronous right ovarian clear cell carcinoma and an incidental left ovarian endometrioid carcinoma with immunohistochemical study.

Authors:  Siddhi G S Khandeparkar; Sanjay D Deshmukh; Hemant S Lekawale; Amit Bhoge; Ansari Tabassum Parveen Maqbool Ahmed
Journal:  J Midlife Health       Date:  2014-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.